Neopharm says software-based catheter enhances treatment for brain tumor patients

By Elaine Rigoli

Tampa, Fla., April 26 - NeoPharm, Inc. said the use of a novel software-based catheter planning and positioning system developed by BrainLAB AG may optimize the efficacy and safety of tumor-targeting therapies delivered via convection enhanced delivery (CED), specifically cintredekin besudotox (IL13-PE38QQRR), an investigational treatment being studied for the treatment of patients with first recurrent glioblastoma multiforme.

Investigators evaluated and assessed the clinical usefulness of a novel simulation algorithm using magnetic resonance diffusion tensor imaging to predict the distribution of a drug administered via CED, according to a news release.

Overall, investigators said the new software simulation technique provides valuable patient-specific information including volume, location and geometry of potential drug distribution.

Using the methods from this study, neurosurgeons will be able to pre-operatively simulate where drugs, such as cintredekin besudotox, are distributed in the brain allowing for greater catheter placement optimization, which may yield improved survival benefits for patients, officials said.

BrainLAB, based in Munich, Germany, is a medical technology developer.

NeoPharm, based in Waukegan, Ill., is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of cancer drugs for therapeutic applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.